CTOs on the Move

ifa united I tech

www.ifa4emr.com

 
ifa united I tech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ifa4emr.com
  • 1850 SE 17th St Ste 107
    Fort Lauderdale, FL USA 33316
  • Phone: 954.618.6277

Executives

Name Title Contact Details

Similar Companies

Initia Medical

Initia Medical is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sound-Eklin

Sound-Eklin is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cagent Vascular

Cagent Vascular is leading the way for next generation technology for vessel dilatation.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.

Valeritas

Valeritas is committed to developing and commercializing innovative treatment solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of Type 2 diabetes. Valeritas` portfolio is headlined by the V-Go® disposable insulin delivery device, which is being commercialized and reimbursed in a specialty pharmaceutical model and is distributed through retail pharmacy.